inclusion criteria: adult patients aged 18-75 years has sars-cov-2-positive antigen or molecular diagnostic test (validated sars-cov-2 antigen, rt-pcr, or other molecular diagnostic assay from a sample collected no more than 7 days prior to enrollment. at least two signs or symptoms of disease consistent with acute covid-19 infection. one of these two symptoms must include cough or shortness of breath with onset within 7 days prior to randomization. other symptoms that qualify include: fever nausea vomiting diarrhea muscle aches fatigue headache loss of smell or taste others that are consistent with acute covid-19 infection in the opinion of the investigator. able and willing to give written or oral informed consent willing to be an outpatient from study day 1 to 14, to provide blood during patient visits on study days 1, 3, 5, and 10, return on study days 1, 3, 5, 7, 10, 14, and 21 for assessment. willing to keep a diary of pain medication usage, side effects, and covid-19 associated symptoms and answer a follow-up questionnaire on study day 84.

inclusion criteria: adult patients aged 18-75 years has sars-cov-2-positive antigen or molecular diagnostic test (validated sars-cov-2 antigen, rt-pcr, or other molecular diagnostic assay from a sample collected no more than 7 days prior to enrollment. at least two signs or symptoms of disease consistent with acute covid-19 infection. one of these two symptoms must include cough or shortness of breath with onset within 7 days prior to randomization. other symptoms that qualify include: fever nausea vomiting diarrhea muscle aches fatigue headache loss of smell or taste others that are consistent with acute covid-19 infection in the opinion of the investigator. able and willing to give written or oral informed consent willing to be an outpatient from study day 1 to 14, to provide blood during patient visits on study days 1, 3, 5, and 10, return on study days 1, 3, 5, 7, 10, 14, and 21 for assessment. willing to keep a diary of pain medication usage, side effects, and covid-19 associated symptoms and answer a follow-up questionnaire on study day 84.

inclusion criteria: 1. adult patients aged 18-75 years 2. has sars-cov-2-positive antigen or molecular diagnostic test (validated sars-cov-2 antigen, rt-pcr, or other molecular diagnostic assay from a sample collected no more than 7 days prior to enrollment. 3. at least two signs or symptoms of disease consistent with acute covid-19 infection. one of these two symptoms must include cough or shortness of breath with onset within 7 days prior to randomization. other symptoms that qualify include: 1. fever 2. nausea 3. vomiting 4. diarrhea 5. muscle aches 6. fatigue 7. headache 8. loss of smell or taste 9. others that are consistent with acute covid-19 infection in the opinion of the investigator. 4. able and willing to give written or oral informed consent 5. willing to be an outpatient from study day 1 to 14, to provide blood during patient visits on study days 1, 3, 5, and 10, return on study days 1, 3, 5, 7, 10, 14, and 21 for assessment. 6. willing to keep a diary of pain medication usage, side effects, and covid-19 associated symptoms and answer a follow-up questionnaire on study day 84.

inclusion criteria: 1. adult patients aged 18-75 years 2. has sars-cov-2-positive antigen or molecular diagnostic test (validated sars-cov-2 antigen, rt-pcr, or other molecular diagnostic assay from a sample collected no more than 7 days prior to enrollment. 3. at least two signs or symptoms of disease consistent with acute covid-19 infection. one of these two symptoms must include cough or shortness of breath with onset within 7 days prior to randomization. other symptoms that qualify include: 1. fever 2. nausea 3. vomiting 4. diarrhea 5. muscle aches 6. fatigue 7. headache 8. loss of smell or taste 9. others that are consistent with acute covid-19 infection in the opinion of the investigator. 4. able and willing to give written or oral informed consent 5. willing to be an outpatient from study day 1 to 14, to provide blood during patient visits on study days 1, 3, 5, and 10, return on study days 1, 3, 5, 7, 10, 14, and 21 for assessment. 6. willing to keep a diary of pain medication usage, side effects, and covid-19 associated symptoms and answer a follow-up questionnaire on study day 84.